Second Trimester Maternal Urine for the Diagnosis of Trisomy 21 and Prediction of Poor Pregnancy Outcomes

resumo

Given the recognized lack of prenatal clinical methods for the early diagnosis of preterm delivery, intrauterine growth restriction, preeclampsia and gestational diabetes mellitus, and the continuing need for optimized diagnosis methods for specific chromosomal disorders (e.g., trisomy 21) and fetal malformations, this work sought specific metabolic signatures of these conditions in second trimester maternal urine, using 'H Nuclear Magnetic Resonance (H-1 NMR) metabolomics. Several variable importance to the projection (VIP)- and b-coefficient-based variable selection methods were tested, both individually and through their intersection, and the resulting data sets were analyzed by partial least-squares discriminant analysis (PLS-DA) and submitted to Monte Carlo cross validation (MCCV) and permutation tests to evaluate model predictive power. The NMR data subsets produced significantly improved PLS-DA models for all conditions except for pre-premature rupture of membranes. Specific urinary metabolic signatures were unveiled for central nervous system malformations, trisomy 21, preterm delivery, gestational diabetes, intrauterine growth restriction and preeclampsia, and biochemical interpretations were proposed. This work demonstrated, for the first time, the value of maternal urine profiling as a complementary means of prenatal diagnostics and early prediction of several poor pregnancy outcomes.

palavras-chave

ACID-CONCENTRATIONS; PRENATAL DISORDERS; VARIABLE SELECTION; METABOLIC PROFILE; OXIDATIVE STRESS; AMNIOTIC-FLUID; DOWN-SYNDROME; METABONOMICS; BIOMARKERS; PLASMA

categoria

Biochemistry & Molecular Biology

autores

Diaz, SO; Barros, AS; Goodfellow, BJ; Duarte, IF; Galhano, E; Pita, C; Almeida, MD; Carreira, IM; Gil, AM

nossos autores

agradecimentos

The group acknowledges funding from the European Regional Development Fund-FEDER through the Competitive Factors Thematic Operational Programme-COMPETE and the Foundation for Science and Technology-FCT, Portugal (PEst-C/CTM/LA0011/2011, PEst-C/QUI/U10062/2011, PTDC/QUI/66523/2006). S.O.D. thanks FCT for SFRH/BD/64159/2009 grant. A.M.G. acknowledges the Portuguese National NMR Network (RNRMN), supported with FCT funds, and M. Spraul, Bruker BioSpin, Germany, for access to software and spectral databases.

Partilhe este projeto

Publicações similares

Usamos cookies para atividades de marketing e para lhe oferecer uma melhor experiência de navegação. Ao clicar em “Aceitar Cookies” você concorda com nossa política de cookies. Leia sobre como usamos cookies clicando em "Política de Privacidade e Cookies".